Private company

NexImmune, Inc.

In its 2024 annual report the company says: “We are a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It has been further developed and optimized by NexImmune following its formation in 2011.”4 It is headquartered in Gaithersburg, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersGaithersburg, United States2
  • Incorporated inDE3
  • Business address9119 Gaither Road, Gaithersburg, Md 208783
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493005RDYAV26LAQ9302
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49931102

See how the biggest companies compare on our leaderboards

We are a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-60.8%Return on equity5
-$48.1MFree cash flow6

Financial statements

Revenue7$0 in 2021
02020: $0$020202021: $0$02021
Operating income76-$53.3M in 2021+91% since 2020
-$60.0M-$40.0M-$20.0M02020: -$27.9M-$27.9M20202021: -$53.3M-$53.3M2021+91%
Net income76-$50.9M in 2021+70% since 2020
-$60.0M-$40.0M-$20.0M02020: -$29.9M-$29.9M20202021: -$50.9M-$50.9M2021+70%
Fiscal year201920202021
Revenue$07$07
Research and development$17.8M7$37.5M6
Operating expenses$53.3M6
Operating income-$27.9M7-$53.3M6
Interest$1.7M7$905.3K6
Income tax$07$06
Net income-$29.9M7-$50.9M6
Earnings per share-$26.427-$2.546
Earnings per share (diluted)-$26.427-$2.546
Shares (weighted, basic)20.2M shares6
Shares (weighted, diluted)20.2M shares6

Compare NexImmune, Inc. with another company

Corporate structure

NexImmune, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NexImmune, Inc.

  • Sol J. Barer Filed SC 13D on NexImmune, Inc., latest Apr 7, 2023 (3 filings since Feb 11, 2022)
  • ArrowMark Colorado Holdings LLC Filed SC 13G/A on NexImmune, Inc., latest Feb 15, 2023 (2 filings since Feb 14, 2022)
  • Artal International S.C.A. Filed SC 13G/A on NexImmune, Inc., latest Feb 13, 2023
  • B&S NexImmune Holdco LLC Filed SC 13G/A on NexImmune, Inc., latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • Louise F. Brady Filed SC 13G on NexImmune, Inc., latest Feb 22, 2022
  • Robert E. Long Jr. Filed SC 13G on NexImmune, Inc., latest Feb 18, 2022
  • Piedmont Capital Partners, LLC Filed SC 13G on NexImmune, Inc., latest Feb 14, 2022
  • NexImmune, Inc. Gaithersburg, Maryland, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NexImmune, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.9M5 Dec 31, 2023$7.7M5 Dec 31, 2022−62.2%
Accumulated depreciation$1.6M5 Dec 31, 2023$3.2M5 Dec 31, 2022−51.9%
Property and equipment, net$1.4M5 Dec 31, 2023$4.5M5 Dec 31, 2022−69.7%
Operating-lease assets (leased space)$46.7K5 Dec 31, 2023$967.0K5 Dec 31, 2022−95.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.2M5 Dec 31, 2023$34.6M5 Dec 31, 2022−90.8%
Marketable securities, current$06 Dec 31, 2022$51.5M6 Dec 31, 2021−100.0%

Leadership

Who has led NexImmune, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Scott Carmer2021
  2. Kristi Jones2022–2024

President

  1. Scott Carmer2021
  2. Kristi Jones2022–2024

Chief financial officer

  1. John Trainer2021–2023

Chief operating officer

  1. Kristi Jones2021
2025
Board members and other officers (13)

Timeline

  1. Aug 27, 20248-K Executive or director change; Other events25
  2. Aug 15, 20248-K Shareholder vote26
  3. Aug 2, 20248-K Shareholder vote; Other events27
  4. Jul 19, 20248-K Shareholder vote; Other events28
  5. Jul 11, 20248-K Listing notice or transfer; Shareholder vote; Other events29
  6. Jun 11, 20248-K Unregistered sale of shares; Change to shareholders' rights; Bylaws or fiscal year changed30
  7. Apr 5, 20248-K Executive or director change31
  8. Feb 5, 20248-K Entered a material agreement; Unregistered sale of shares; Shareholder vote32
  9. Feb 2, 20248-K Ended a material agreement33
  10. Feb 1, 20248-K Other events34
  11. Jan 19, 20248-K Shareholder vote; Other events35
  12. Dec 22, 20238-K Shareholder vote; Other events36
  13. Mar 30, 2022New chief executive Kristi Jones becomes CEO10
  14. Feb 11, 2021New chief executive Scott Carmer becomes CEO11
  15. Jun 7, 2011Founded NexImmune, Inc. is founded2

Calendar

When it reported results

  1. Aug 10, 2023Reported quarterly or annual results37
  2. May 15, 2023Reported quarterly or annual results38
  3. Mar 28, 2023Reported quarterly or annual results39
  4. Nov 14, 2022Reported quarterly or annual results40
  5. Aug 15, 2022Reported quarterly or annual results41
  6. May 12, 2022Reported quarterly or annual results42
  7. Mar 9, 2022Reported quarterly or annual results43
  8. Nov 12, 2021Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

149 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 40 major events, 51 insider forms, 11 large holders, 35 other. The latest 20:

  1. Aug 28, 2024EFFECT EDGAR
  2. Aug 27, 2024S-8 POS EDGAR
  3. Aug 27, 2024S-8 POS EDGAR
  4. Aug 27, 2024S-8 POS EDGAR
  5. Aug 27, 2024POS AM EDGAR
  6. Aug 27, 20248-K EDGAR
  7. Aug 15, 20248-K EDGAR
  8. Aug 7, 202410-Q EDGAR
  9. Aug 2, 2024DEFA14A EDGAR
  10. Aug 2, 20248-K EDGAR
  11. Jul 19, 2024DEFA14A EDGAR
  12. Jul 19, 20248-K EDGAR
  13. Jul 11, 2024DEFA14A EDGAR
  14. Jul 11, 20248-K EDGAR
  15. Jun 21, 2024DEF 14A EDGAR
  16. Jun 13, 20244 EDGAR
  17. Jun 11, 2024PRE 14A EDGAR
  18. Jun 11, 20248-K EDGAR
  19. May 20, 202410-Q EDGAR
  20. May 15, 2024NT 10-Q EDGAR

The 149 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 21 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 11, 2024Jones KristiPresident and CEOBuy1$0.01Form 4
Nov 22, 2023Roemer Alan S.DirectorSale3,992$1.94$7.7KForm 4
Nov 21, 2023Roemer Alan S.DirectorSale3,833$2.16$8.3KForm 4
Mar 30, 2023BARER SOL JDirectorBuy400,000$0.41$164.0KForm 4
Nov 17, 2022BARER SOL JDirectorBuy75,000$0.48$36.0KForm 4
Nov 16, 2022BARER SOL JDirectorBuy125,000$0.48$60.0KForm 4
Jun 7, 2022Verstandig GrantDirectorBuy26,876$2.28$61.3KForm 4
Jun 6, 2022Verstandig GrantDirectorBuy25,000$2.14$53.5KForm 4
Jun 3, 2022Verstandig GrantDirectorBuy15,000$2.22$33.3KForm 4
Jun 2, 2022Verstandig GrantDirectorBuy47,900$2.23$106.8KForm 4
Jun 2, 2022BARER SOL JDirectorBuy20,720$2.22$46.0KForm 4
Jun 1, 2022Verstandig GrantDirectorBuy40,200$2.38$95.7KForm 4
Jun 1, 2022BARER SOL JDirectorBuy40,000$2.35$94.0KForm 4
May 31, 2022Verstandig GrantDirectorBuy45,024$2.11$95.0KForm 4
May 31, 2022BARER SOL JDirectorBuy39,280$2.19$86.0KForm 4
Mar 29, 2022Jones KristiPresident and CEOBuy10,000$3.74$37.4KForm 4
Mar 28, 2022Verstandig GrantDirectorBuy18,983$3.76$71.4KForm 4
Mar 25, 2022Verstandig GrantDirectorBuy131,622$4.14$544.9KForm 4
Mar 24, 2022Verstandig GrantDirectorBuy39,995$3.35$134.0KForm 4
Mar 23, 2022BARER SOL JDirectorBuy10,000$2.67$26.7KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How NexImmune, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNexImmune, Inc.1
  • CIK0001538210
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9119 Gaither Road, Gaithersburg, MD 208781
  • Phone301-825-98101
  • Shares outstanding1,394,671 as of Aug 7, 20249
  • Public float$5.8M as of Jun 30, 20235
  • On EDGAR sinceFeb 3, 20121
  • Filings217 in all: 4 (70), 8-K (43), 3 (15), 10-Q (11), D (7), DEFA14A (7), SC 13G (7), DEF 14A (5)1
    All 36 form types

    SC 13G/A (5), 10-K (4), 424B5 (3), CORRESP (3), EFFECT (3), PRE 14A (3), S-8 (3), S-8 POS (3), 144/A (2), NT 10-Q (2), S-1/A (2), SEC STAFF LETTER (2), UPLOAD (2), 144 (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-K (1), POS AM (1), S-1 (1), S-1MEF (1), S-3 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Apr 16, 2024
    Quarterly report (10-Q) Aug 7, 2024
    Proxy statement (DEF 14A) Jun 21, 2024
    Latest 8-K (8-K) Aug 27, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51